These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 15871548

  • 1. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study.
    Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G, CODE-2 Italian Advisory Board.
    Treat Endocrinol; 2003; 2(2):121-33. PubMed ID: 15871548
    [Abstract] [Full Text] [Related]

  • 2. The impact of diabetes mellitus on healthcare costs in Italy.
    Giorda CB, Manicardi V, Diago Cabezudo J.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-19. PubMed ID: 22098288
    [Abstract] [Full Text] [Related]

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Dec; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 4. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004.
    van der Linden MW, Plat AW, Erkens JA, Emneus M, Herings RM.
    Value Health; 2009 Sep; 12(6):909-14. PubMed ID: 19508664
    [Abstract] [Full Text] [Related]

  • 5. Costs of treatment and complications of adult type 1 diabetes.
    Franciosi M, Lucisano G, Amoretti R, Capani F, Bruttomesso D, Di Bartolo P, Girelli A, Leonetti F, Morviducci L, Vitacolonna E, Nicolucci A.
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):606-11. PubMed ID: 22749531
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S.
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Direct health care costs of diabetic patients in Spain.
    Oliva J, Lobo F, Molina B, Monereo S.
    Diabetes Care; 2004 Nov; 27(11):2616-21. PubMed ID: 15504995
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach.
    Marcellusi A, Viti R, Mecozzi A, Mennini FS.
    Eur J Health Econ; 2016 Mar; 17(2):139-47. PubMed ID: 25427540
    [Abstract] [Full Text] [Related]

  • 12. [Cost of diabetes mellitus in Spain].
    González P, Faure E, Del Castillo A, Grupo de Trabajo para el Estudio del Coste de la Diabetes.
    Med Clin (Barc); 2006 Nov 25; 127(20):776-84. PubMed ID: 17198665
    [No Abstract] [Full Text] [Related]

  • 13. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A, Navarro-Artieda R, Morano R, Ruíz L.
    Endocrinol Nutr; 2016 Dec 25; 63(10):527-535. PubMed ID: 27744013
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug 25; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U, Chaiyakunapruk N, Dilokthornsakul P, Thavorn K, Saokaew S.
    Appl Health Econ Health Policy; 2016 Jun 25; 14(3):281-92. PubMed ID: 26961276
    [Abstract] [Full Text] [Related]

  • 16. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 25; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 17. Type 2 diabetes and healthcare resource utilisation in the Kingdom of Bahrain.
    Salman RA, AlSayyad AS, Ludwig C.
    BMC Health Serv Res; 2019 Dec 05; 19(1):939. PubMed ID: 31805932
    [Abstract] [Full Text] [Related]

  • 18. Costs of diabetes and its complications in Poland.
    Leśniowska J, Schubert A, Wojna M, Skrzekowska-Baran I, Fedyna M.
    Eur J Health Econ; 2014 Jul 05; 15(6):653-60. PubMed ID: 23820625
    [Abstract] [Full Text] [Related]

  • 19. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB, Rossi MC, Ozzello O, Gentile S, Aglialoro A, Chiambretti A, Baccetti F, Gentile FM, Romeo F, Lucisano G, Nicolucci A, HYPOS-1 Study Group of AMD.
    Nutr Metab Cardiovasc Dis; 2017 Mar 05; 27(3):209-216. PubMed ID: 28017523
    [Abstract] [Full Text] [Related]

  • 20. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar 05; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.